ABSTRACT
BACKGROUND: Dehydroepiandrosterone (DHEA) derived from adrenal cortex has an indirect bioeffect through differentiating into androgen or estrogen in the related peripheral tissues. OBJECTIVE: To verify the effects and mechanisms of DHEA on promoting osteoblasts (OBs) proliferation. DESIGN, TIME AND SETTING: The grouping controlled experiment was accomplished in Shanghai Sixth People's Hospital affiliated to Shanghai Jiao Tong University and Institute of Radiation Medicine, Fudan University from January 2006 to February 2007. MATERIALS: Ten SD rats were recruited, 1 day old, regardless of gender. DHEA was the product of American Sigma Company. METHODS: Rat OBs were separated and cultured in vitro. First generation of OBs cultured in a varied concentrations of DHEA (1?10-5, 1?10-7 and 1?10-9 mmol/L) for 72 hours were set up as the experiment group, while those exposed to 1?10-8 mmol/L of estradiol culture were regarded as positive controls and blank control group was set up as well. MAIN OUTCOME MEASURES: The OBs were identified by cell morphology and alkaline phosphatase (ALP) dyeing. Light microscope and methyl thiazolyl tetrazolium assay were used to detect the growth and proliferation of OBs. The formation of mineralized nodus was examined by alizarin bordeaux stain. The concentrations of osteoprotegerin in DHEA culture solution were also measured by double antibody sandwich ABC-ELISA simultaneously. RESULTS: ①Identification of primarily cultured OBs showed ALP dyeing was positive.②Proliferation rate of OBs was increased in experiment groups compared with that of the blank control group, and the most significant increase occurred in the concentration of 1?10-7 mmol/L DHEA culture (P 0.05).③ALP activity in experiment groups was higher, especially in the group with the concentration of 1?10-7 mmol/L DHEA (P 0.05).④ALP activity of unitary cell population was higher in 1?10-9 mmol/L DHEA culture group than that in blank control group (P
ABSTRACT
AIM:Although there are many evidences showing positive effects of dehydroepiandrosterone sulfate(DHEA-S) in bone metabolism,the reasonable and thorough experiments are still needed to clear the mechanism of DHEA-S on bone metabolism by excluding the biological effect of its derivative hormone.This experiment is to study the efficacy and safety of DHEA-S in treatment of osteoporosis in elderly males.METHODS:①From October 2005 to October 2006,120 out-and in-patients with primary osteoporosis who were admitted in Shanghai 6th People's Hospital were selected.The diagnosis of primary osteoporosis referred to the new standard from WHO:without the application of sexual hormone,and over 2.5 standard deviation value of bone mineral density lower than the peak value of the same gender subject.All the cases were randomly divided into treatment group and control group(60 cases in every group).② DHEA-S 100 mg and Caltrate-D 600 mg were orally given to the treatment group;Caltrate-D 600 mg was orally given to the control group.③After 6 months,the bone density,serum biochemical markers,markers of bone resorption and formation as well as side effects were measured.RESULTS:120 osteoporosis patients entered into analysis.①Compared to the pretreatment and control group,the bone mineral density in lumbar spine 1,lumbar spine 2-4,femoral neck,and upper part of femoral bone were increased significantly in the treatment group(P 0.05).CONCLUSION:Treatment of osteoporosis in elderly males with DHEA-S is safe and effective without obvious side effects.
ABSTRACT
Objective:To study the effects of Somatostatin-14 and-8 on portal hemodynamics and plasma levels of the insulin-like growth factor(IGF-1),nitric oxide(NO),endothelin-1(ET-1) and glucagon(GLU) in patients with portal hypertension after transjugular intrahepatic portosystemic shunt(TIPS). Methods:Fourteen portal hypertension patients underwent TIPS,their portal pressures directly measured by the intravenous catheter placed in the portal vein,the hemodynamic changes observed and the plasma levels of IGF-1,NO,ET-1 and GLU determined before and 8 and 24 hours after the infusion of Somatostatin-14 or-8 according to a cross-over design.Results:The average decrease in portal pressure after the intravenous infusion of Somatostatin-14 and-8 was(9.4?1.0) cmH2O and(5.0?1.0) cmH2O,respectively(P0.05) 8 and 24 hours after the infusion.Conclusion:Both Somatostatin-14 and-8 can significantly reduce portal pressure,although the former is more potent than the latter.The underlying mechanism may involve their inhibition of the secretion of GLU,IGF-1 and other hormones as well as their reduction of hepatic metabolism and portal inflow.
ABSTRACT
<p><b>OBJECTIVE</b>To study the effect of dehydroepiandrosterone sulfate (DHEAS) treatment of osteoporosis in men with T(BMD) > or = 2.5SD.</p><p><b>METHODS</b>Eighty-six patients were randomly divided into two groups: treatment group (n = 44) and control group (n = 42). DHEAS (100 mg q.d.) was given to the treatment group for 6 months. Bone mineral density, (BMD), biochemical markers of bone absorption and formation and other serum biochemical markers were measured before and after DHEAS treatment. Drug side effects were also evaluated.</p><p><b>RESULTS</b>After oral administration of DHEAS (100 mg q.d.) for 6 months, the serum concentrations of DHEAS and IGF-I in the treatment group were 93.75% +/- 16.1% and 17.71% +/- 4.2% higher respectively than those in the control group (P < 0.01). The BMD of L2, L3, L4, L2 - 4 and Neck sections increased in the treatment group by 2.65% +/- 0.65%, 2.70% +/- 0.48%, 3.10% +/- 0.41%, 2.82% +/- 0.37% and 2.32% +/- 0.31%, respectively, as compared with that the control group (P < 0.05 or 0.01). No significant changes were observed in serum FT, E(2) and PSA concentrations in the treatment group as compared with the control group.</p><p><b>CONCLUSION</b>The treatment of osteoporosis in men with DHEAS is safe and effective.</p>
Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Bone Density , Dehydroepiandrosterone Sulfate , Therapeutic Uses , Osteoporosis , Drug TherapyABSTRACT
Objectives The purpose of this study was to compare the effect of somatostatin and octreotide on portal vein pressure in portal hypertensive patients.KG*2MethodsWT5”BZ Portal pressure in 12 patients with portal hypertension after TIPS was measured directly by means of a cathater placed in portal vein after infusion of somatostatin (6 mg/24h) or octreotide(0 6 mg/h). The drugs was infused intravenously and alternatively in each individual patient on day 1 or day 3 after TIPS. Portal pressure was assessed at baseline and at 1、2、4、6、8、12、24、30、36 hours after infusion of each drug.KG*2ResultsKG1The average decrease of portal pressure was 9 4?1 0 cm H 2 O and 5 0?1 0 cm H 2 O respectively after the intravenous infusion of somatostatin or octreotide( P